Skip to main content
SpringerLink
Log in

CLL-Rezidivtherapie für Multimorbide

  • Literatur kompakt_Leukämien und Lymphome
  • Published:
Im Focus Onkologie Aims and scope

Bei ernsten Begleiterkrankungen wird die Chemotherapie eines Rezidivs ­einer chronischen lymphatischen Leukämie (CLL) schwierig. Gezielte ­Therapien sollen hier einspringen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  • Furman RR et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Friederike Klein

Authors
  1. Friederike Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Klein, F. CLL-Rezidivtherapie für Multimorbide. Im Focus Onkologie 17, 20 (2014). https://doi.org/10.1007/s15015-014-1201-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-014-1201-3

Search

Navigation